世界のがん免疫療法市場(~2026):市場機会・投与量・価格・臨床試験インサイト

◆英語タイトル:Global Cancer Immunotherapy Market Opportunity, Dosage, Price and Clinical Trials Insight 2026
◆商品コード:KUIK21FB017
◆発行会社(リサーチ会社):Kuick Research
◆発行日:2020年2月
◆ページ数:600
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Single userUSD4,000 ⇒換算¥456,000見積依頼/購入/質問フォーム
Multi UserUSD6,900 ⇒換算¥786,600見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はKuick Research社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Kuick Research社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

本市場調査レポートでは、世界のがん免疫療法市場について調査・分析を行い、イントロダクション、がん免疫療法の種類、市場動向、がんワクチン、モノクローナル抗体、T細胞療法、免疫療法における免疫チェックポイント阻害剤の応用、がん免疫療法における免疫調節剤の役割、腫瘍溶解性ウイルス免疫療法の開発、サイトカイン&がん免疫療法、免疫療法におけるインターフェロン、免疫療法におけるインターロイキン、免疫療法におけるGM-CSF、がん免疫療法の市場的側面、がん免疫療法パイプラインの概要、可用性・価格・投与量・売上分析、市販用癌細胞療法薬、市販用がんサイトカイン薬、市販用癌ワクチン、市販用癌モノクローナル抗体、今後の展望、競争状況などを掲載しています。
・イントロダクション
・がん免疫療法の種類
・市場動向
・がんワクチン
・モノクローナル抗体
・T細胞療法
・免疫療法における免疫チェックポイント阻害剤の応用
・がん免疫療法における免疫調節剤の役割
・腫瘍溶解性ウイルス免疫療法の開発
・サイトカイン&がん免疫療法
・免疫療法におけるインターフェロン
・免疫療法におけるインターロイキン
・免疫療法におけるGM-CSF
・がん免疫療法の市場的側面
・がん免疫療法パイプラインの概要
・可用性・価格・投与量・売上分析
・市販用癌細胞療法薬
・市販用がんサイトカイン薬
・市販用癌ワクチン
・市販用癌モノクローナル抗体
・今後の展望
・競争状況
【レポートの概要】

“Global Cancer Immunotherapy Market Opportunity, Dosage, Price and Clinical Trials Insight 2026″ Report Highlights:

Global Cancer Immunotherapy Market Opportunity: > US$ 200 Billion
Cancer Immunotherapy Clinical Trials: > 2300 Drugs In Trials
Commercially Available Cancer Immunotherapies: > 120
Cancer Vaccines Market Opportunity: > US$ 20 Billion
Cancer Monoclonal Antibodies Market Opportunity: > US$ 90 Billion
Marketed Cancer Monoclonal Antibodies’: > 70 mAbs
Sales, Market Opportunity, Dosage and Price Data: 300 Graphs/Charts
Clinical Trials Insight By Phase, Company, Patient Segment, Drug Class

The research report “Global Cancer Immunotherapy Market Opportunity, Dosage, Price and Clinical Trials Insight 2026” discusses the implications that the recent scientific research and development has brought, in context to the ongoing trends and current size of the cancer immunotherapy at global and regional level. Additionally, the report depicts the nature of the therapies and the structures that are followed by the cancer immunotherapy approach, with detailed profiles of the pharmaceutical companies that are the keynote representer of immunotherapy products in the market.

“Cancer Immunotherapy Has Emerged As Next Growth Frontier With US$ 200 Billion In Market Opportunity For Multiple Stake Holders Involved In The Research and Development Of Anti Cancer Therapies”

The immunotherapy defends the normal cells by activating the body’s immune system against the cancerous cells. The immunotherapy attractively summons the manipulated body’s own natural immune cells and causes the eviction of the cancer cells. The cancer immunotherapy techniques such as T-cell therapy, Immune checkpoint inhibitors, Cancer vaccines, Monoclonal Antibodies and many more have offered the cancer patients with no or less hope and with substantial benefit of meaningful improvements. The growth of the respective market is attributed to the advantage that it provides of being a potential one-time treatment with long and durable response.

Different cancer immunotherapies have been developed and successfully marketed across the globe for various malignancies. They may differ in modality but all of them have some common features due to which they are in high demand among cancer patients. Development of results is apparently rapid than other cancer treatment leading to quick alleviation of clinical symptoms. As a result, more cancer patients want them to improve their medical condition in shorter time.

Improved anti-cancer efficacy is another major benefit of cancer immunotherapies which is not offered by other modalities. Fewer side effects are observed during cancer immunotherapy treatment resulting in higher tolerability and improved quality of life. Relapse prevention and increased progression free survival are also improved resulting in increased demand for cancer immunotherapies. Investigators are trying to decipher more underlying principles of cancer immunotherapies in order to offer better medical care to patients.

The aim with which the cancer immunotherapy approach came into existence was to escalate the process of cancer treatment which largely went unnoticed during usage of traditional technologies. Advanced manipulations in all the therapies of cancer immunotherapy have placed the approach above all the other available therapies for cure of cancer. The ease and the technological performance of the therapies results in long term survival of the cancer patients and a more comfortable after treatment life due to the absence of unwanted chemicals in the body and thus leading to less severe side effects. The approach has enhanced the already existing cancer treatment techniques and has marked itself as an important discovery in the field of oncology.

The strategies that are employed by the immunotherapy approach are playing a very important part in the overall medication for the cancer and that has led to the successful and rapid expansion of the overall immunotherapy market in a very short period of time. The cancer immunotherapy market is driven by the fact that the methodologies working under it have a strong clinical pipeline among which monoclonal antibodies constitutes the most widely accepted immunotherapeutic approach at the global level. The impressive rate at which the market is growing is representing a state of progress that the approach will follow in the near future.

【レポートの目次】

Immunotherapy for Cancer

1.1 Introduction to Cancer Immunotherapy
1.2 Advancement of Cancer Immunotherapy

Types of Cancer Immunotherapy

2.1 Specific Cancer Immunotherapy
2.1.1 Cancer Vaccines
2.1.2 Monoclonal Antibodies

2.2 Non-Specific Cancer Immunotherapy
2.2.1 Adoptive Cell Transfer Immunotherapy
2.2.2 Immune Checkpoint Inhibitors

Dynamics of Global Cancer Immunotherapy Landscape

3.1 Favorable Developmental and Commercialization Parameters
3.2 Issues to be Resolved in Expansion of Immunotherapy Horizon

Cancer Vaccines: Transforming The Immunotherapy Landscape

4.1 Prologue of Cancer Vaccines
4.2 Cancer Vaccines in Immunotherapy
4.3 Commercialization of Cancer Vaccines

Monoclonal Antibodies: New Era of Immunotherapy

5.1 Rudiments of Monoclonal Antibodies
5.2 Advents of Monoclonal Antibodies
5.3 Commercial Aspects of Monoclonal Antibodies

Trails of T-Cell Therapies

6.1 Adoptive Cell Transfer Technology
6.2 Strategies of Adoptive Cell Transfer
6.3 Commercial Aspects of Adoptive Cell Therapy

Application of Immune Checkpoint Inhibitors in Immunotherapy

7.1 Prelude to Immune Checkpoint Inhibitors
7.2 Implications of Immunecheck Point Inhibitors
7.3 Commercial Aspects of Immune Checkpoint Inhibitors

Role of Immunomodulators in Cancer Immunotherapy

8.1 Perspective of Immunomodulators
8.2 Clinical Aspects of Immunomodulators
8.3 Commercial Aspects of Immunomodulators

Development of Oncolytic Viral Immunotherapy

9.1 Concept to Oncolytic Viruses
9.2 Potential Approaches of Oncolytic Viruses
9.3 Commercial Aspects of Oncolytic Viruses

Cytokines and Cancer Immunotherapy

10.1 Fundamentals of Cytokines
10.2 Classification of Cytokines
10.3 Commercial Aspects of Cytokines

Interferons in Immunotherapy

11.1 Potentials of Interferons
11.2 Classification of Interferons
11.3 Clinical Applications of Interferons

Interleukins in Immunotherapy

12.1 Potentials of Interleukins
12.2 Clinical Applications of Interleukins

GM-CSF in Immunotherapy

13.1 Potentials of GM-CSF
13.2 Clinical Applications of GM-CSF

Market Aspects of Cancer Immunotherapy

14.1 Current Market Trends
14.2 Economic Aspects of Cancer Immunotherapy
14.3 Cancer Immunotherapy Cost by Product

Cancer Immunotherapy Pipeline Overview

15.1 By Drug Class
15.2 By Phase
15.3 By Company
15.4 By Target
15.5 By Patient Segment

Cancer Immune Check Point Inhibitors – Availability, Price, Dosage and Sales Analysis

16.1 Keytruda (Pembrolizumab)
16.2 Yervoy (Ipilimumab)
16.3 Opdivo (Nivolumab)
16.4 Tecentriq (Atizolizumab)
16.5 Bavencio (Avelumab)
16.6 Imfinzi (Darlumuvab)
16.7 Libtayo (Cemiplimab)

Cancer Monclonal Antibody Market – Availability, Price, Dosage and Sales Analysis

17.1 Herceptin (Trastuzumab)
17.2 Avastin (Bevacizumab)
17.3 MabThera/Rituxan (Rituximab)
17.4 Erbitux (Cetuximab)
17.5 Vectibix (Panitumab)
17.6 Arzerra (Ofatumumab)
17.7 Gazyva (Obinutuzumab)
17.8 Perjeta (Pertuzumab)

Bispecific Antibody Market – Availability, Price, Dosage and Sales Analysis

18.1 Blincyto (Blinatumomab)

Cancer Vaccine Market – Availability, Price, Dosage and Sales Analysis

19.1 Gardasil and Gardasil 9
19.2 Cervarix
19.3 Provenge (Sipuleucel – T)
19.4 Vaxira (Racotumomab)
19.5 CreaVax-RCC

Cancer Cytokines Drugs Market – Availability, Price, Dosage and Sales Analysis

20.1 Proleukin (Aldeslukin)
20.2 Intron A (Interferon Alpha-2b)
20.3 PegIntron (PegInterferon alpha-2b)
20.4 Sylatron (Peginterferon Alpha-2b)
20.5 Betaseron (Interferon Beta-1b)
20.6 Actimmune (Interferon Gamma-1b)
20.7 Ontak (Denileukin Diftitox)

Oncolytic Virus Market – Availability, Dosage, and Price Analysis

21.1 Imlygic
CAR-T Cell Therapy – Availability, Dosage, Price and Sales Analysis
22.1 Kymriah
22.2 Yescarta

Marketed Cancer Cell Therapies Drugs

23.1 T-Lymphocyte Cell Therapy(Immuncell-LCandreg;)
23.2 Zalmoxis
23.3 APCEDEN For RCC
23.4 Dendritic Cell-Activated Cytokine-Induced Killer Cells – Shanghai Jia Fu Medical

Marketed Cancer Cytokines Drugs

24.1 Aldesleukin (Proleukinandreg;)
24.2 Denileukin Diftitox (ONTAKandreg;)
24.3 Interferon Alpha (Multiferonandreg;)
24.4 Interferon Alpha-2a (Roferon-Aandreg;)
24.5 Interferon Alpha-2a (Veldonaandreg;)
24.6 Interferon Alpha-2a Biosimilar(Inferonandtrade;/Inmutagandtrade;)
24.7 Interferon Alpha-2b(Intronandreg; A)
24.8 Interferon Alpha-2b Biosimilar(Bioferonandtrade;)
24.9 Interferon Alpha-2b Biosimilar (Intalfaandreg;)
24.10 Interferon Alpha-2b Biosimilar
24.11 Interferon Alpha-2b Biosimilar (ReliFeronandreg;)
24.12 Interferon-Alpha-n3 (Alferon Nandreg;)
24.13 Interferon-Beta-1b (Feronandreg;)
24.14 Interferon-Gamma (Ogammaandreg;)
24.15 Interleukin-2 Biosimilar (Ilcass)
24.16 Teceleukin (Imunaceandtrade;)

Marketed Cancer Vaccines

25.1 Bladder Cancer Vaccine (PACISandreg;)
25.2 Bladder Cancer Vaccine
25.3 BV NSCLC 001
25.4 Dendritic Cell Vaccine (CreaVax-HCCandreg;, CreaVax-PCandreg; and CreaVax-RCCandreg;)
25.5 Human Papillomavirus Vaccine Quadrivalent (Gardasilandreg;/Silgardandreg;)
25.6 Human Papillomavirus Vaccine Recombinant Bivalent (Cervarixandreg;)
25.7 Immuvac / Cadi 05
25.8 Immucyst / TheraCys
25.9 Melanoma Vaccine (MVaxandreg;)
25.10 Melanoma Vaccine (Melacineandreg;)
25.11 Racotumomab (Vaxiraandreg;)
25.12 Reniale
25.13 Sipuleucel-T (Provengeandreg;)
25.14 Tertomotide (LucaVax)
25.15 Vitespen (Oncophageandreg;)

Marketed Cancer Monoclonal Antibodies

26.1 Bevacizumab
26.2 Trastuzumab Emtansine
26.3 Trastuzumab Subcutaneous
26.4 Brentuximab Vedotin
26.5 Catumaxomab
26.6 Ipilimumab
26.7 Nivolumab
26.8 Pembrolizumab
26.9 Pertuzumab
26.10 Rituximab
26.11 Trastuzumab
26.12 Gemtuzumab Ozogamicin
26.13 Others

Global Cancer Immunotherapy Market Future Prospects

Competitive Landscape

28.1 Abbvie
28.2 Advaxis
28.3 Altor BioScience
28.4 Amgen
28.5 Biogen Idec
28.6 Biogenomics
28.7 Celldex Therapeutics
28.8 Dendreon Corporation
28.9 Eli Lilly
28.10 Expression Genetics
28.11 Galena Biopharma
28.12 Genmab
28.13 Gilead Sciences
28.14 GlaxoSmithKline
28.15 ImmunoCellular Therapeutics
28.16 ImmunoGen
28.17 Inovio Pharmaceuticals
28.18 IRX Therapeutics
28.19 Merck
28.20 NeoStem Oncology
28.21 NewLink Genetics
28.22 Northwest Biotherapeutics
28.23 Novartis
28.24 Peregrine Pharmaceuticals
28.25 Pfizer
28.26 Philogen
28.27 Regulon
28.28 Roche
28.29 Seattle Genetics
28.30 ZymoGenetics



【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[世界のがん免疫療法市場(~2026):市場機会・投与量・価格・臨床試験インサイト]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆